Zellweger Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recently, the use of experimental models led to the identification of a gene encoding for a peroxisomal membrane protein (PAF-1) in which a mutation was associated with the altered phenotype in a complementation group of the Zellweger syndrome (paradigm of these diseases).
|
8507691 |
1993 |
Zellweger Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
This gene encodes a protein that shows similarity to the mammalian PAF1 protein (Zellweger syndrome).
|
7600573 |
1995 |
Peroxisomal Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Per6p has significant overall sequence similarity with the human peroxisome assembly factor PAF-1, a protein that is defective in certain patients suffering from the peroxisomal disorder Zellweger syndrome, and with car1, a protein required for peroxisome biogenesis and caryogamy in the filamentous fungus Podospora anserina.
|
8628321 |
1996 |
Peroxisome biogenesis disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The first, functional complementation, was established as a viable approach by Fujiki and colleagues, who identified PAF-1, the first known peroxisome biogenesis disorder gene.
|
8993569 |
1996 |
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Taken together, these findings link the tumor suppressor parafibromin to the transcription elongation and RNA processing pathway as a PAF1 complex- and RNA polymerase II-bound protein.
|
15923622 |
2005 |
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis.
|
16491129 |
2006 |
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis.
|
16491129 |
2006 |
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis.
|
16491129 |
2006 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Its core subunit, PD2/hPaf1, is amplified and overexpressed in many cancers.
|
17599057 |
2007 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Further, an overexpression of PD2/hPaf1 results in the induction of a transformed phenotype, suggesting its possible involvement in tumorigenesis.
|
17599057 |
2007 |
Hyperparathyroidism-Jaw Tumor Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a familial cancer syndrome that can result from germline inactivation of HRPT2/CDC73, a putative tumor suppressor gene that encodes parafibromin, a component of the transcriptional regulatory PAF1 complex with homology to the yeast protein Cdc73p.
|
20304979 |
2010 |
Pancreatic carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
Malignant neoplasm of pancreas
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Simian Immunodeficiency Viruses and HIV-2 are also restricted in PAF1 expressing cells.
|
22082156 |
2011 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour.
|
25099282 |
2014 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We find that Paf1 undergoes ubiquitylation and is degraded by the 26S proteasome in yeast, thus deciphering UPS regulation of an evolutionarily conserved factor, Paf1, involved in various cellular processes at the crossroads of the cancer networks.
|
29023102 |
2017 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Our results showed that the Pd(II) complex was more cytotoxic to cancer cells than noncancer cell lines and caused cell death through apoptotic pathways.
|
28657910 |
2017 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
We find that Paf1 undergoes ubiquitylation and is degraded by the 26S proteasome in yeast, thus deciphering UPS regulation of an evolutionarily conserved factor, Paf1, involved in various cellular processes at the crossroads of the cancer networks.
|
29023102 |
2017 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results showed that the Pd(II) complex was more cytotoxic to cancer cells than noncancer cell lines and caused cell death through apoptotic pathways.
|
28657910 |
2017 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The treatment of the Pd(II) complex in tumor-bearing mice effectively reduced the tumor size at half the dose used for cisplatin.
|
28657910 |
2017 |